Latest Security News

Eagle Mountain Mining has completed a significant placement of nearly 95.4 million new shares and over 31.8 million options to address the shortfall from its recent entitlement offer, reinforcing its capital base as it advances copper-gold projects in Arizona.

APC Minerals has bolstered its financial footing with a $1.765 million capital raise, setting the stage for a strategic review and management transition as it evaluates its gold and critical minerals projects.

Pantera Minerals has completed a $40 million divestment of its Smackover Lithium Project, pivoting strategically into U.S. critical minerals with a major land acquisition in Arkansas. The company’s strengthened balance sheet and expanded U.S. market presence set the stage for accelerated growth.

E79 Gold Mines has significantly expanded its Western Australian footprint by acquiring a 90% stake in Cue Metals, gaining access to the highly prospective Cue Gold Project in the Murchison region. The company has also launched a high-resolution gravity survey and reported promising exploration results across its key projects.

8common Limited reported a positive EBITDA for the first half of FY26 alongside a 4% increase in SaaS revenue, supported by significant operational cost reductions and key contract renewals.

Critica Limited has addressed a recent spike in its share price and trading volume, attributing the movement to positive research coverage while confirming no undisclosed information is driving the activity.

Pioneer Minerals has advanced its US critical minerals portfolio with promising high-grade tungsten and gold results at North Pine, alongside uranium exploration progress, supported by a $1 million capital raise.

Mt Malcolm Mines NL has taken a major step forward with the acquisition of a 500,000 tonnes per annum gold processing plant and an oversubscribed $3.05 million capital raise, while drilling at Picnic South confirms consistent near-surface gold mineralisation.

FINEOS Corporation Holdings PLC reports a robust €27.8 million cash balance at the end of 2025, maintaining its FY25 revenue guidance despite seasonal cash flow dips and currency fluctuations.

Paradigm Biopharmaceuticals has secured independent validation of its Phase 2 iPPS biomarker study, published in a leading rheumatology journal, reinforcing the scientific basis for its Phase 3 osteoarthritis trial.

Epsilon Healthcare has posted a record $2.891 million in receipts for the December 2025 quarter, nearly doubling year-on-year revenue and marking a significant turnaround with its recent ASX reinstatement.

Aeeris Ltd has reported a profitable second quarter for FY26, with total unadjusted revenue rising 61% year-on-year to $1.54 million and annual recurring revenue climbing 16.5% to nearly $4 million. The company’s operational advances and disciplined cost control underpin a promising path to sustainable profitability.